US 11,976,133 B2
Bispecific T cell engagers
Margaret Karow, Newbury Park, CA (US); Richard Yau, Newbury Park, CA (US); and Jackie Sheng, Newbury Park, CA (US)
Assigned to Gensun Biopharma Inc., Newbury Park, CA (US)
Filed by Gensun Biopharma Inc., Newbury Park, CA (US)
Filed on Feb. 1, 2021, as Appl. No. 17/164,699.
Claims priority of provisional application 62/968,999, filed on Jan. 31, 2020.
Prior Publication US 2021/0246222 A1, Aug. 12, 2021
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/3092 (2013.01) [A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01)] 10 Claims
 
1. A polypeptide comprising two antigen binding fragments of anti-DLL3 antibodies,
wherein the polypeptide comprises:
a first polypeptide chain comprising an antigen binding fragment of a first anti-DLL3 antibody in svfc form, wherein the antigen binding fragment of the first anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:7, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:14, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:27, and a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:31, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:40, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:47;
a second polypeptide chain comprising a heavy chain of a second anti-DLL3 antibody, wherein the heavy chain of the second anti-DLL3 antibody comprises a heavy chain variable region comprising heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:16, and heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:24; and
a third polypeptide chain comprising a light chain of the second anti-DLL3 antibody, wherein the light chain of the second anti-DLL3 antibody comprises a light chain variable region comprising light chain CDR1 comprising the amino acid sequence of SEQ ID NO:33, light chain CDR2 comprising the amino acid sequence of SEQ ID NO:43, and light chain CDR3 comprising the amino acid sequence of SEQ ID NO:49,
wherein the first anti-DLL3 antibody and the second anti-DLL3 antibody bind to different epitopes of DLL3.